Minor and clinically non-significant interaction between toloxatone and amitriptyline

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Psychopharmacology

Background:

• Amitriptyline is a widely used tricyclic antidepressant.
• Toloxatone is a novel, reversible inhibitor of monoamine oxidase A (MAO-A).
• Potential pharmacokinetic interactions between co-administered drugs can alter therapeutic efficacy and safety profiles.

Purpose of the Study:

• To evaluate the pharmacokinetic interaction between amitriptyline (AMT) and toloxatone in depressed patients.
• To determine the effect of toloxatone on the plasma levels and urinary excretion of amitriptyline and its metabolites.
• To assess if patient metabolic status influences the observed drug interaction.

Main Methods:

• Seventeen depressed in-patients receiving steady-state amitriptyline were studied.
• Amitriptyline and its metabolites (demethylated and hydroxylated) were measured in blood and urine.
• Dextromethorphan phenotyping was used to determine patients' metabolic status.
• Measurements were taken with and without concurrent steady-state toloxatone administration.

Main Results:

• A minor pharmacokinetic interaction was observed, indicated by a small increase in the amitriptyline/nortriptyline plasma ratio (0.68 to 0.78).
• Co-administration of toloxatone did not significantly affect the plasma levels or urinary excretion of amitriptyline and its metabolites.
• The metabolic status of patients (including poor metabolizers) did not predict the magnitude of the drug interaction.

Conclusions:

• The pharmacokinetic interaction between amitriptyline and toloxatone is clinically insignificant.
• Routine plasma level monitoring of amitriptyline is not warranted when co-administered with toloxatone.
• The findings support the safety of combining these two medications in depressed patients.